Antibodies for 2020: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(No difference)
|
Latest revision as of 13:26, 20 January 2020
EPCAM, CD45 and egfr PD1/PD-1, BRAC, HRD, EGFR, T790M, TMB and MSI. EpCAM*CD3,
TrionPharma公司的Catumaxomab（靶向CD3和EpCAM）
Amgen（安进）公司的Blincyto（Blinatumomab，靶向CD3和CD19）
罗氏的Emicizumab（靶向凝血因子X和因子IXa）